Biểu đồ giá cổ phiếu AVTX
AVTX Dự đoán giá cổ phiếu
Avalo Therapeutics Inc
$20.25
-6.11%
$-1.32
Khi đóng cửa: May 11, 16:00:00 GMT-4
$20.2
-0.24%
$-0.05
Phiên trước giờ: May 12, 07:38:39 GMT-4
Quay lại
Avalo Therapeutics Inc (AVTX) Dự đoán giá cổ phiếu
Thống kê chính
Giá đóng cửa trước
$21.57
Giá mở cửa
$21.86
Phạm vi ngày
$19.8 - $22.02
Phạm vi 52 tuần
$3.39 - $20.72
Khối lượng
2.8M
Khối lượng trung bình
630.2K
Tỷ suất cổ tức
--
EPS (TTM)
-6.39
Vốn hóa thị trường
$539.5M
AVTX là gì?
Avalo Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the treatment of immune dysregulation by developing therapies that target the LIGHT-signaling network. The company is headquartered in Wayne, Pennsylvania and currently employs 33 full-time employees. The company went IPO on 2015-11-13. The firm's lead asset is AVTX-009, an anti-IL-1β mAb, targeting inflammatory diseases. AVTX-009 is a humanized monoclonal antibody (IgG4) that binds to interleukin-1β (IL-1β) with high affinity and neutralizes its activity. IL-1β is a central driver in the inflammatory process. Overproduction or dysregulation of IL-1β is implicated in many autoimmune and inflammatory diseases. IL-1β is a major, validated target for therapeutic intervention. There is evidence that inhibition of IL-1β could be effective in hidradenitis suppurativa and a variety of inflammatory diseases in dermatology, gastroenterology, and rheumatology. AVTX-009 is in the Phase II LOTUS trial for hidradenitis suppurativa (HS).
